Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab.
Phase of Trial: Phase IV
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Ocrelizumab (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 01 Jun 2017 Status changed from not yet recruiting to recruiting.
- 19 May 2017 New trial record